On Monday, Eli Lilly And Co (NYSE:LLY) announced results from two Phase 3 studies of mirikizumab across two types of inflammatory bowel diseases (IBD). The studies showed patients treated with ...
Ulcerative colitis is a type of inflammatory bowel disease (IBD) that causes inflammation of the colon, and leads to symptoms such as fatigue, abdominal pain, and cramping. There is currently no cure ...
At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive symptoms, including bowel ...
Eli Lilly and Co. (NYSE:LLY) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of ...
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy now. On October 7, Eli Lilly and Company announced new data from the LUCENT-3 Phase 3 open-label extension study demonstrating ...
(RTTNews) - Johnson & Johnson (JNJ) Monday reported positive data from Phase 3 QUASAR long-term extension study of TREMFYA in adults with moderately-to-severely active ulcerative colitis (UC). Results ...
What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...
Tremfya is a brand-name medication used to treat moderate to severe ulcerative colitis in adults by targeting a protein that reduces inflammation in the large intestine. Treatment with Tremfya ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results